title: Role of pre-junctional CB1, but not CB2 , TRPV1 or GPR55 receptors in anandamide-induced inhibition of the vasodepressor sensory CGRPergic outflow in pithed rats.
abstract: Stimulation of the perivascular sensory outflow in pithed rats produces vasodepressor responses mediated by CGRP release. Interestingly, endocannabinoids such as anandamide (which interacts with CB1 , CB2 , TRPV1 and GPR55 receptors) can regulate the activity of perivascular sensory nerves in dural blood vessels by modulating CGRP release. Yet, as no publication has reported whether this mechanism is operative in the healthy systemic vasculature, this study has specifically analysed the receptors mediating the potential inhibitory effects of the cannabinoid (CB) receptor agonists anandamide (non-selective), JWH-015 (CB2 ) and lysophosphatidylinositol (GPR55) on the rat vasodepressor sensory CGRPergic outflow (an index of systemic vasodilatation). Healthy pithed rats were pre-treated with consecutive i.v. continuous infusions of hexamethonium, methoxamine and the above agonists. Electrical spinal (T9 -T12 ) stimulation of the vasodepressor sensory CGRPergic outflow or i.v. injections of α-CGRP produced frequency-dependent or dose-dependent vasodepressor responses. The infusions of anandamide in a dose-dependent manner inhibited the vasodepressor responses by electrical stimulation (remaining unaffected by JWH-015 or lysophosphatidylinositol), but not those by α-CGRP. After i.v. administration of antagonists, the inhibition by 3.1 μg/kg min anandamide was: (i) potently blocked by 31-100 μg/kg NIDA41020 (CB1 ), (ii) unaffected by 180 μg/kg AM630 (CB2 ), 31 μg/kg cannabidiol (GPR55) or 31-100 μg/kg capsazepine (TRPV1) and (iii) slightly blocked by 310 μg/kg AM630. The above doses of antagonists were enough to block their respective receptors. These results suggest that anandamide-induced inhibition of the vasodepressor sensory CGRPergic outflow is mainly mediated by pre-junctional activation of CB1 receptors, with no pharmacological evidence for the role of CB2 , TRPV1 or GPR55 receptors.
authors.affiliation: Departamento de Famacobiología, Cinvestav-Coapa, Col. Granjas-Coapa, Deleg, Tlalpan, México D.F., México.
authors.forename: Bruno A
authors.initials: BA
authors.lastname: Marichal-Cancino
authors.forename: Alain H
authors.initials: AH
authors.lastname: Altamirano-Espinoza
authors.forename: Guadalupe
authors.initials: G
authors.lastname: Manrique-Maldonado
authors.forename: Antoinette
authors.initials: A
authors.lastname: MaassenVanDenBrink
authors.forename: Carlos M
authors.initials: CM
authors.lastname: Villalón
mesh_terms: D000818:Animals; D001095:Arachidonic Acids / Q000494:pharmacology*; D015740:Calcitonin Gene-Related Peptide / Q000378:metabolism*; D063386:Cannabinoid Receptor Agonists / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004558:Electric Stimulation; D063388:Endocannabinoids / Q000494:pharmacology*; D007211:Indoles / Q000494:pharmacology; D008246:Lysophospholipids / Q000494:pharmacology; D008297:Male; D053284:Polyunsaturated Alkamides / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D043884:Receptor, Cannabinoid, CB1 / Q000187:drug effects* / Q000378:metabolism; D014664:Vasodilation / Q000187:drug effects*
chemical_list: D001095:Arachidonic Acids; D063386:Cannabinoid Receptor Agonists; D063388:Endocannabinoids; D007211:Indoles; D008246:Lysophospholipids; D053284:Polyunsaturated Alkamides; D043884:Receptor, Cannabinoid, CB1; C025449:lysophosphatidylinositol; D015740:Calcitonin Gene-Related Peptide; C094023:iodopravadoline; C078814:anandamide; C402944:JHW 015